DXR - Daxor Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
6.11
+0.03 (+0.49%)
At close: 3:29PM EDT
Stock chart is not supported by your current browser
Previous Close6.08
Open6.13
Bid0.00 x 1100
Ask0.00 x 900
Day's Range6.11 - 6.18
52 Week Range3.40 - 21.66
Volume2,148
Avg. Volume30,674
Market Cap22.782M
Beta-1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.33
Earnings DateN/A
Forward Dividend & Yield0.03 (0.46%)
Ex-Dividend Date2018-01-05
1y Target Est30.00
Trade prices are not sourced from all markets
  • ACCESSWIRE21 days ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • GlobeNewswirelast month

    Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development

    NEW YORK, June 12, 2018-- Daxor Corporation, an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Kathryn A. Kornafel as ...

  • GlobeNewswire2 months ago

    Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an investigator-initiated trial at Virginia Commonwealth University Medical Center that will incorporate the company’s patented BVA-100 diagnostic to assess blood volume loss during burn surgery. "Intravascular volume and red cell mass management are unquestionably important determinants of outcomes in critically ill patients. More so than others, burn patients represent a particularly vulnerable population to significant volume/red cell derangements.

  • GlobeNewswire2 months ago

    Daxor Corporation to Present at the LD Micro 8th Annual Invitational on June 4, 2018

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at the LD Micro Invitational Conference on Monday June 4, 2018 at 4:30 PM Pacific Time. Daxor Corporation is an innovative medical instrumentation and biotechnology company.

  • GlobeNewswire2 months ago

    Daxor Corporation Retains CORE IR as Investor Relations Firm of Record

    Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces it has retained CORE IR as its Investor Relations firm of record. Core IR will provide comprehensive investor relations and shareholder communications services and assist the company in expanding market awareness and engagement with the institutional and retail investment communities. CORE IR is a leading boutique investor relations firm, specializing in leveraging the most effective investment, growth and exposure strategies for small to mid-sized companies through an integrated approach to relationship development and shareholder communications.

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks

    Ahead of today's trading session, WallStEquities.com scans Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Halyard Health Inc. (NYSE: HYH). Companies in the Medical Instruments and Supplies space manufacture and sell medical devices, instrument systems, and reagents and consumables.

  • Are Daxor Corporation’s (NYSEMKT:DXR) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Daxor Corporation’s (NYSEMKT:DXR) Interest Costs Too High?

    While small-cap stocks, such as Daxor Corporation (AMEX:DXR) with its market cap of US$28.93M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Daxor and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / March 16, 2018 / Daxor shares were skyrocketing in Thursday trading with gains as high as over 130% after physician-researchers of Mayo Clinic presented new positive findings ...

  • ACCESSWIRE4 months ago

    Daxor, Analysis of the BVA-100 Updates, Financial Data, and Product Review

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Daxor Corporation (NYSEMKT:DXR): Time For A Financial Health Check
    Simply Wall St.6 months ago

    Daxor Corporation (NYSEMKT:DXR): Time For A Financial Health Check

    Daxor Corporation (AMEX:DXR) is a small-cap stock with a market capitalization of $19.48M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • Daxor Corp. : DXR-US: Dividend Analysis : December 21st, 2017 (record date) : By the numbers : December 28, 2017
    Capital Cube7 months ago

    Daxor Corp. : DXR-US: Dividend Analysis : December 21st, 2017 (record date) : By the numbers : December 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Daxor Corp. with the following peers – LeMaitre Vascular, Inc., Nephros, Inc. and CytoSorbents Corporation (LMAT-US, NEPH-US and CTSO-US). Daxor Corp.’s dividend yield is 0.63 percent and its dividend payout is 7.88 percent. This compares to a peer average dividend yield of 0.66 percent and ... Read more (Read more...)

  • Did Daxor Corporation’s (NYSEMKT:DXR) Earnings Growth Outperform The Industry?
    Simply Wall St.7 months ago

    Did Daxor Corporation’s (NYSEMKT:DXR) Earnings Growth Outperform The Industry?

    After looking at Daxor Corporation’s (AMEX:DXR) latest earnings announcement (30 June 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • Daxor Corporation (DXR): Risks You Need To Consider Before Buying
    Simply Wall St.8 months ago

    Daxor Corporation (DXR): Risks You Need To Consider Before Buying

    If you are looking to invest in Daxor Corporation’s (AMEX:DXR), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Marketwired10 months ago

    Daxor Corporation Forwarding Plans to Expand Impact at HFSA 2017 and Beyond

    Daxor Corporation , an investment company with medical instrumentation and biotechnology operations, announced today that it will be exhibiting at the 21st meeting of the Heart Failure Society of America ...